Iqvia Rises As It Buys Charles River's Early: stage drug research assets

IQVIA Holdings

25/02/2026 13:42

** Shares of contract research firm IQVIA Holdings IQV.N rise 2.26% to $167.77 premarket

**  Co says it will acquire five Charles River CRL.N labs that work on early-stage drug discovery

**  Deal expands co's platform in oncology, neurology, immunology, metabolism and rare diseases - IQV

** Co says move strengthens ability to support pharma and biotech clients from early discovery through clinical development

**  Financial terms undisclosed; transaction expected to close in Q2, co says

** Stock up ~15% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))